Methyl 5-methyl-2-[(3R)-3-methylmorpholin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naphthyridine-4-carboxylate
C19H21N5O3 — CID 130228837
Data last refreshed: (MolForge compound catalog, from PubChem)
About Methyl 5-methyl-2-[(3R)-3-methylmorpholin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naphthyridine-4-carboxylate
Methyl 5-methyl-2-[(3R)-3-methylmorpholin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naphthyridine-4-carboxylate (PubChem CID 130228837) has the molecular formula C19H21N5O3 and a molecular weight of 367.41 g/mol. Its IUPAC name is methyl 5-methyl-2-[(3R)-3-methylmorpholin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naphthyridine-4-carboxylate.
Molecular Properties
| Compound Name | Methyl 5-methyl-2-[(3R)-3-methylmorpholin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naphthyridine-4-carboxylate |
|---|---|
| PubChem CID | 130228837 |
| Molecular Formula | C19H21N5O3 |
| Molecular Weight | 367.41 g/mol |
| Exact Mass | 367.16 |
| IUPAC Name | methyl 5-methyl-2-[(3R)-3-methylmorpholin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naphthyridine-4-carboxylate |
| SMILES | COC(=O)c1cc(N2CCOC[C@H]2C)nc2c(-c3ccn[nH]3)ncc(C)c12 |
| InChI | InChI=1S/C19H21N5O3/c1-11-9-20-17(14-4-5-21-23-14)18-16(11)13(19(25)26-3)8-15(22-18)24-6-7-27-10-12(24)2/h4-5,8-9,12H,6-7,10H2,1-3H3,(H,21,23)/t12-/m1/s1 |
| InChIKey | ICRLFNNZXAVRSM-GFCCVEGCSA-N |
| XLogP | 2.34 |
| TPSA | 93.23 Ų |
| H-Bond Donors | 1 |
| H-Bond Acceptors | 7 |
| Rotatable Bonds | 3 |
| Heavy Atoms | 27 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 367.41 |
| LogP ≤ 5 | 2.34 |
| H-Bond Donors ≤ 5 | 1 |
| H-Bond Acceptors ≤ 10 | 7 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 130228837 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.